HALO vs SPRY
HALO: Halozyme is a biopharmaceutical company that licenses its proprietary drug-delivery technology to help pharmaceutical partners convert intravenous treatments into more convenient subcutaneous injections. SPRY: Biopharmaceutical company commercializing neffy, the only FDA-approved needle-free intranasal epinephrine for emergency anaphylaxis treatment.
Side-by-side fundamentals
| Metric | HALO | SPRY | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $103.12 | $6.16 | |
| Market cap as of 2026-08-10 | $12.2B | $612M | |
| P/E as of 2026-08-10 | 29.57 | n/a | |
| PEG as of 2026-08-10 | 0.94 | -0.00 | SPRY lower |
| Net margin as of 2026-08-10 | +24.9% | -200.0% | HALO higher |
| Gross margin as of 2026-08-10 | +82.4% | +74.1% | HALO higher |
| Operating margin as of 2026-08-10 | +35.6% | -204.5% | HALO higher |
| ROE as of 2026-08-10 | +180.6% | -153.6% | HALO higher |
| ROA as of 2026-08-10 | +16.6% | -60.9% | HALO higher |
| Debt / equity as of 2026-08-10 | 14.95 | 1.57 | SPRY lower |
| Revenue growth (YoY) as of 2026-08-10 | +41.1% | +1.9% | HALO higher |
| Revenue CAGR (3y) SEC XBRL | +28.4% | +300.1% | SPRY higher |
| Beta as of 2026-08-10 | 0.90 | 0.82 | |
| 1-year return as of 2026-08-07 close | +66.1% | -65.1% | HALO higher |
Fundamentals: market data, as of 2026-08-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.